<DOC>
	<DOCNO>NCT00547651</DOCNO>
	<brief_summary>This study drug ( Amrubicin ) believe work stop tumor cell body grow . The purpose study evaluate effect amrubicin compare topotecan treatment small cell lung cancer .</brief_summary>
	<brief_title>AMR PH GL 2007 CL001 Phase 3 Trial Patients With Small Cell Lung Cancer After Failure First-Line Chemotherapy</brief_title>
	<detailed_description>Small cell lung cancer represent approximately 13 % cancer lung present extensive stage disease 60 % 70 % patient . Sites metastasis include bone ( 35 % ) , liver ( 25 % ) , bone marrow ( 20 % ) , brain ( 10 % ) , extrathoracic lymph node ( 5 % ) , subcutaneous mass ( 5 % ) . Small-cell lung cancer prominent marker neuroendocrine differentiation . The stag classification SCLC 2-stage Veterans Administration Lung Study Group system categorize patient limited extensive disease . Limited stage SCLC disease confine 1 hemithorax without adjacent mediastinal and/or supraclavicular lymph node involvement , without pleural effusion . This extent disease include tolerable radiation field . Extensive-disease SCLC disease beyond definition limited-stage disease . There proven treatment option SCLC patient fail first-line chemotherapy . New treatment strategy must evaluate . The need discover active agent well toxicity profile continue great importance . Amrubicin may effective treatment population .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Amrubicin</mesh_term>
	<criteria>Histological cytological diagnosis SCLC study entry accord International Association Study Lung Cancer ( IASLC ) histopathologic classification . Mixed combine subtypes accord IASLC allow ; SCLC either sensitive ( defined response include stable disease firstline platinumbased chemotherapy , subsequent progression &gt; /= 90 day complete firstline chemotherapy ) refractory ( define best response firstline platinumbased chemotherapy progression &lt; 90 day complete firstline chemotherapy ) ; Extensive limit disease ; patient limited disease candidate local regional salvage radiation therapy must offer treatment prior participation study ; Radiographically document progression firstline treatment platinumbased chemotherapy ; No 1 prior chemotherapy regimen ; At least 18 year age ; ECOG performance status 0 1 Chest radiotherapy curative intent primary disease complex &lt; /= 28 day prior first dose ; CNS radiotherapy &lt; /= 21 day prior first dose ; radiotherapy area &lt; /= 7 day prior first dose ; Prior anthracycline , topotecan , irinotecan treatment . Prior anthracycline topotecan treatment . Patients know history seropositive human immunodeficiency virus ( HIV ) patient receive immunosuppressive medication would increase risk serious neutropenic complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Limited Disease Sensitive Small Cell Lung Cancer</keyword>
	<keyword>Extensive Disease Sensitive Small Cell Lung Cancer</keyword>
	<keyword>Limited Disease Refractory Small Cell Lung Cancer</keyword>
	<keyword>Extensive Disease Refractory Small Cell Lung Cancer</keyword>
	<keyword>Refractory Small Cell Lung Cancer</keyword>
	<keyword>Sensitive Small Cell Lung Cancer</keyword>
</DOC>